Commentary

Ketamine formulation study is ‘groundbreaking’

Publish date: April 24, 2018

 

References

1. Biol Psychiatry. 2016 Sep 15;80(6):424-31.

2. JAMA Psychiatry. 2018 Feb 1;75(2):139-48.

3. Am J Psychiatry. 2018 Apr 16. doi: 10.1176/appi.ajp.2018.17060720.

4. Am J Psychiatry. 2018 Apr 1;175(4]):327-35.

5. Psychol Med. 2015 Dec;45(16):3571-80.

6. Am J Psychiatry. 2018 Feb 1;175(2):150-8.

7. Am J Psychiatry. 2016 Aug 1;173(8):816-26.

Pages

Recommended Reading

Little treatments show big promise for youth psychiatric problems
Clinician Reviews
‘Motivational pharmacotherapy’ engages Latino patients with depression
Clinician Reviews
Opioid deaths and suicides – twin tragedies that need a community-wide response
Clinician Reviews
Early births stress dads too
Clinician Reviews
Use of opioids, SSRIs linked to increased fracture risk in RA
Clinician Reviews
Hormone therapy may reduce depressive symptoms in early menopause
Clinician Reviews
Serotonin syndrome warnings magnify its rare probability
Clinician Reviews
Serotonin syndrome risk with triptans and antidepressants ‘very low’
Clinician Reviews
Depression risks identified in women
Clinician Reviews
Suicide prevention, NRA team up for safer gun storage
Clinician Reviews